Bavituximab is under clinical development by Feng Biosciences and currently in Phase II for Glioblastoma Multiforme (GBM). According to GlobalData, Phase II drugs for Glioblastoma Multiforme (GBM) have a 23% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Bavituximab’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Bavituximab overview
Bavituximab (Tarvacin) is under development for the treatment of rectal adenocarcinoma, glioblastoma multiforme, gliosarcoma, advanced hepatocellular carcinoma, gastric and gastroesophageal junction adenocarcinoma. The drug candidate is administered as an intravenous infusion. Bavituximab is phosphotidylserine (PS)-targeting antibody. It was also under development for the treatment of non-small cell lung cancer, castration resistant prostate cancer, pancreatic ductal adenocarcinoma, hepatitis C, melanoma, triple-negative breast cancer and HER2 negative metastatic breast cancer, progressive recurrent/metastatic squamous cell carcinoma of the head and neck cancer and metastatic breast cancer. It being developed based on RNA expression-based biomarker platform.
It was under development for the treatment of viral hemorrhagic fever and Ebola viral infections.
Feng Biosciences overview
Feng Biosciences is a biotechnology company engaged in research and development of novel therapies for the treatment of solid tumors and other cancer diseases. The company is headquartered in Waltham, Massachusetts, the US.
For a complete picture of Bavituximab’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
